19th April 2020
doDOC can be used for remote reviewing and editing of documents
Recently accepted for EIT Health Bridghead support, doDOC is a cloud-based editor for editing and reviewing scientific and regulatory documentation.
During the COVID-19 pandemic, doDOC offers special conditions to Life Science Companies (Pharma, Biotech, Research) with a minimum of 50 users.
doDOC does not require the installing of any software, which makes it especially useful during this pandemic for Life Science companies with staff working from home.
By using doDOC, staff can keep working remotely and it can even increase the flow of collaborations among teams.
The application enables users to edit and review a document simultaneously in real-time, while keeping tight control of permissions and versions. This avoids the potential security risks associated with sending documents over email.
This offer becomes more valuable for pharmaceutical companies and research groups that need to keep developing their work from home, while ensuring that they work under the umbrella of an enterprise application with the security levels required in these use cases.
The main difference between doDOC and other editors is that, besides the real-time full editing and review capabilities, doDOC registers every action executed in a document, ensuring compliance with EU Annex 11.
ASK: Research contributors needed for CON-VICE study
University of Luxembourg needs European researchers to get in touch
OFFER: Funding available for COVID-19 research
Fondation Air Liquide are looking to fund European projects
ASK: Supporting the immunocompromised
Partners sought to advance neutralising antibody